文献速递消化、代谢与肾脏急症

托法替布治疗对TNF抑制剂应答不佳的银屑病关节炎患者

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
PubMed 文献 · N Engl J Med · 2017-01-01
一句话结论对TNF抑制剂应答不佳的活动性银屑病关节炎患者,托法替布5 mg或10 mg每日两次治疗3个月ACR20应答率约50%,高于安慰剂24%。

这项6个月随机、安慰剂对照、双盲3期试验纳入395例对TNF抑制剂应答不佳的活动性银屑病关节炎患者,按2:2:1:1随机分为托法替布5 mg每日两次组(132例)、10 mg每日两次组(132例)、安慰剂3个月后换用托法替布5 mg每日两次组(66例)、安慰剂3个月后换用托法替布10 mg每日两次组(65例),前3个月安慰剂组数据合并分析。主要终点为3个月时ACR20应答率和HAQ-DI评分较基线变化。3个月时ACR20应答率托法替布5 mg组50%、10 mg组47%,安慰剂组24%(两项比较均P<0.001);HAQ-DI较基线平均变化分别为-0.39和-0.35,安慰剂组-0.14(两项比较均P<0.001)。持续托法替布组严重不良事件发生率5 mg组4%、10 mg组6%,6个月内发生4例严重感染、3例带状疱疹感染、1例心肌梗死和1例缺血性卒中;持续托法替布组AST和ALT升高至正常上限3倍以上者多于安慰剂后换用托法替布组。

要点

  • 对TNF抑制剂应答不佳的活动性银屑病关节炎患者,托法替布5 mg每日两次组3个月ACR20应答率50%,10 mg每日两次组47%,安慰剂组24%(均P<0.001)。
  • 3个月时HAQ-DI较基线平均变化:托法替布5 mg组-0.39、10 mg组-0.35,安慰剂组-0.14(均P<0.001)。
  • 持续托法替布组严重不良事件发生率5 mg组4%、10 mg组6%;6个月内发生4例严重感染、3例带状疱疹感染、1例心肌梗死、1例缺血性卒中。
  • 持续托法替布组AST和ALT升高至正常上限3倍以上者多于安慰剂后换用托法替布组。
  • 作者结论:对TNF抑制剂应答不佳的活动性银屑病关节炎患者,托法替布3个月内降低疾病活动优于安慰剂,但不良事件更频繁。

适用人群与场景

  • 活动性银屑病关节炎且既往对TNF抑制剂应答不佳的患者(纳入本试验)。

处置流程与药物剂量

  • 托法替布5 mg口服每日两次(132例)。
  • 托法替布10 mg口服每日两次(132例)。
  • 安慰剂3个月后换用托法替布5 mg口服每日两次(66例)。
  • 安慰剂3个月后换用托法替布10 mg口服每日两次(65例)。

研究设计与关键结果

  • 6个月随机、安慰剂对照、双盲3期试验,纳入395例活动性银屑病关节炎且对TNF抑制剂应答不佳患者,按2:2:1:1随机分为托法替布5 mg每日两次组(132例)、10 mg每日两次组(132例)、安慰剂后换用5 mg每日两次组(66例)、安慰剂后换用10 mg每日两次组(65例),前3个月安慰剂组数据合并分析。
  • 3个月ACR20应答率:托法替布5 mg组50%、10 mg组47%,安慰剂组24%(两项比较均P<0.001)。
  • 3个月HAQ-DI较基线平均变化:托法替布5 mg组-0.39、10 mg组-0.35,安慰剂组-0.14(两项比较均P<0.001)。
  • 持续托法替布组严重不良事件发生率5 mg组4%、10 mg组6%。
  • 6个月内持续托法替布组发生4例严重感染、3例带状疱疹感染、1例心肌梗死、1例缺血性卒中。
  • 持续托法替布组AST和ALT升高至正常上限3倍以上者多于安慰剂后换用托法替布组。

证据类型、等级与局限

  • 证据类型:随机、安慰剂对照、双盲3期试验。
  • 资助方:辉瑞;试验注册号OPAL Beyond ClinicalTrials.gov NCT01882439。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对TNF抑制剂应答不佳的活动性银屑病关节炎患者,托法替布3个月内降低疾病活动优于安慰剂,但不良事件较安慰剂更频繁。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors.

METHODS: In this 6-month randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 patients, in a 2:2:1:1 ratio, to four regimens: 5 mg of tofacitinib administered orally twice daily (132 patients); 10 mg of tofacitinib twice daily (132 patients); placebo, with a switch to 5 mg of tofacitinib twice daily at 3 months (66 patients); or placebo, with a switch to 10 mg of tofacitinib twice daily at 3 months (65 patients). Data from the patients who received placebo during the first 3 months of the trial were pooled. The primary end points were the percentage of patients who had at least 20% improvement according to the criteria of the American College of Rheumatology (ACR20 response) and the change from baseline score on the Health Assessment Questionnaire-Disability Index (HAQ-DI; scores range from 0 to 3, with higher scores indicating greater disability) at the month 3 analysis.

RESULTS: At 3 months, the rates of ACR20 response were 50% with the 5-mg dose of tofacitinib and 47% with the 10-mg dose, as compared with 24% with placebo (P<0.001 for both comparisons); the corresponding mean changes from baseline in HAQ-DI score were -0.39 and -0.35, as compared with -0.14 (P<0.001 for both comparisons). Serious adverse events occurred in 4% of the patients who received the 5-mg dose of tofacitinib continuously and in 6% who received the 10-mg dose continuously. Over the course of 6 months, there were four serious infections, three herpes zoster infections, one myocardial infarction, and one ischemic stroke among the patients who received tofacitinib continuously. Elevations of aspartate and alanine aminotransferase concentrations of three or more times the upper limit of the normal range occurred in more patients who received tofacitinib continuously than in patients who received placebo followed by tofacitinib.

CONCLUSIONS: In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 months in reducing disease activity. Adverse events were more frequent with tofacitinib than with placebo. (Funded by Pfizer; OPAL Beyond ClinicalTrials.gov number, NCT01882439 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017. PMID: 29045207. doi:10.1056/NEJMoa1615977

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。